<DOC>
	<DOCNO>NCT00020189</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness flavopiridol treat patient recurrent metastatic head neck cancer .</brief_summary>
	<brief_title>Flavopiridol Treating Patients With Recurrent Metastatic Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine standard response rate ( complete response partial response ) duration response patient recurrent metastatic squamous cell carcinoma head neck treat flavopiridol . - Determine qualitative quantitative toxic effect regimen patient . - Determine progression-free overall survival patient treat regimen . - Determine effect anti-platelet agent , aspirin clopidogrel bisulfate , pharmacology flavopiridol patient . - Determine effect prophylactic anticoagulation anti-platelet agent , aspirin clopidogrel bisulfate , incidence flavopiridol-related thrombosis patient . OUTLINE : Patients receive flavopiridol IV 1 hour day 1-5 . Courses repeat every 3 week absence disease progression unacceptable toxicity . Patients also receive oral aspirin clopidogrel bisulfate begin day 0 continue throughout study . Patients follow death . PROJECTED ACCRUAL : A total 12-37 patient accrue study within 1-3 year .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven squamous cell carcinoma head neck Metastatic disease diagnosis OR Persistent , metastatic , recurrent disease prior definitive surgery and/or radiotherapy No undifferentiated nonkeratinizing carcinoma , include lymphoepitheliomas location No nasopharynx tumor Bidimensionally measurable disease Patients whose measurable disease within prior radiotherapy port must clearly progressive disease No metastatic leptomeningeal CNS disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Platelet count great 100,000/mm^3 Absolute granulocyte count great 1,500/mm^3 Hepatic : See Other ( Prior/Concurrent Therapy ) SGOT SGPT less 2.5 time normal Bilirubin le 1.5 time normal No history hypercoagulopathies ( e.g. , protein C deficiency , protein S deficiency , lupus anticoagulant ) Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Calcium great normal No hypercalcemia refractory bisphosphonates Cardiovascular : No unstable newly diagnose angina pectoris No myocardial infarction within past 6 month No class IIIV congestive heart failure No history symptomatic carotid disease No concurrent asymptomatic carotid artery occlusion ( 70 % great ) one arteries Doppler ultrasound No symptomatic atherosclerosis No thrombotic event within past 6 month Pulmonary : No aspirininduced asthma Other : No inability take aspirin clopidogrel bisulfate due contraindication , allergy , preexist medical condition ( e.g. , active peptic ulcer disease history undiagnosed nonoccult , nonhemorrhoidal gastrointestinal bleeding source within past 6 month ) No prior malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer currently complete remission HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy Chemotherapy : At least 4 week since prior chemotherapy recover No prior flavopiridol No 3 prior systemic chemotherapy regimens recurrent metastatic disease No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy except oral contraceptive Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy recover No concurrent radiotherapy Surgery : See Disease Characteristics At least 4 week since prior surgery recover No prior carotid endarterectomy revascularization surgery Other : No concurrent antineoplastic therapy No active anticoagulation INR 1.5 great No lowmolecular weight heparin equivalent Concurrent bisphosphonates calcium maintenance allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2004</verification_date>
	<keyword>thromboembolism</keyword>
	<keyword>untreated metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>metastatic squamous neck cancer occult primary squamous cell carcinoma</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>salivary gland squamous cell carcinoma</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
</DOC>